Clinical trial
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV…
NCT00309166 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00309166 |
|---|---|
| Title | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. |
| Official title | An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Cervarix vaccine, Engerix-B vaccine |
| Enrollment | 270 |
| Start date | Apr 5, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 19, 2007 |
| First posted | Mar 31, 2006 |
| Last update posted | Sep 17, 2018 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: